CONTACT US

Email: info@alfa-chemistry.com
Tel:1-201-478-8534
1-516-662-5404
Fax: 1-516-927-0118
Address: Suite 212, Waverly Plaza, 755 Waverly Avenue, Holtsville, NY 11742, USA

For product inquiries, please use our online system or send an email to
inquiry@alfa-chemistry.com

chemistry partner
Home > Product > Nanomaterials > Metal Nanomaterials > Nanoparticles & Nanopowders > Hafnium Nanoparticles / Nanopowder

Hafnium Nanoparticles / Nanopowder | CAS Number: 7440-58-6

Catalog Number
ACM7440586
Product Name
Hafnium Nanoparticles / Nanopowder
Structure
CAS Number
7440-58-6
MDL Number
MFCD00011032
Synonyms
Hafnium nanoparticles
Molecular Weight
178.49
Molecular Formula
Hf
Boiling Point
4602°C
Melting Point
2227°C
Density
13.31 g/cm3
Purity
99%, 99.9%, 99.99%, 99.999%
Appearance
Gray powder
Hazard Statements
H251
Electrical resistivity
35.1 microhm-cm @ 25°C
Ratio
Poisson's Ratio 0.37
Young's Modulus
78 GPa
Vickers Hardness
1760 MPa
Thermal Expansion
(25 °C) 5.9 µm·m-1·K-1
Thermal Conductivity
0.230 W/cm/K @ 298.2 K
Specific Heat
0.035 Cal/g/K @ 25 °C
Electronegativity
1.3 Paulings
Heat of Vaporization
155 K-Cal/gm atom at 4602°C
Heat of Fusion
6.0 Cal/gm mole
If you have any other questions or need other size, please get a quote.
  • CAS
  • Size
  • Purity
  • Price
  • Availability
  • Quantity
  • Order
1First-in-Human Study Testing a New Radioenhancer Using Nanoparticles (NBTXR3) Activated by Radiation Therapy in Patients with Locally Advanced Soft Tissue Sarcomas.

Bonvalot S1, Le Pechoux C2, De Baere T2, Kantor G3, Buy X3, Stoeckle E3, Terrier P2, Sargos P3, Coindre JM3, Lassau N2, Ait Sarkouh R4, Dimitriu M4, Borghi E4, Levy L4, Deutsch E2, Soria JC2.

Clin Cancer Res. 2016 Oct 6. doi: 10.1158/1078-0432.CCR-16-1297. [Epub ahead of print]

PURPOSE: This phase I study aimed to determine the recommended dose (RD), safety profile, and feasibility of a procedure combining intratumoral injection of hafnium oxide nanoparticles (NBTXR3; a radioenhancer) and external beam radiotherapy (EBRT) for preoperative treatment of adults with locally advanced soft tissue sarcoma (STS).EXPERIMENTAL DESIGN: Patients had a preoperative indication of EBRT for STS of the extremity or trunk. Read More

Share

Interested in our Services & Products ? Need detailed information?
facebook twitter linkedin google+

Contact us

Email:
Tel:1-201-478-8534
1-516-662-5404
Fax: 1-516-927-0118
Address: Suite 212, Waverly Plaza, 755 Waverly Avenue, Holtsville, NY 11742, USA